AtheroGenics' heart disease drug it's developing with AstraZeneca, did not meet its primary goal in a large, late-stage clinical trial.
But it will continue its development!
AtheroGenic's shares plummeted nearly 60 percent in pre-market trading while AstaZeneca's shares fell.
AZ have 45 days to decide to bail out.
More
1 comment:
They are not the only ones. look at this guys!!
http://www.ottawabusinessjournal.com/288378823795106.php
I guess management at least keep their salaries for some more months, I guess there is no plan B here.
Post a Comment